Antihyperglycemics
- Drug choice is now comorbidity-first
- SGLT2 → HF/CKD benefit
- GLP-1/GIP-GLP-1 → weight + ASCVD benefit
- Metformin remains a common inexpensive base
- Insulin if severe/catabolic hyperglycemia
- Sulfonylurea: cheap but hypo + weight gain
- Match therapy to goals, cost + kidney function
Class at a glance
- Drug choice is now comorbidity-first
Members / distinctions
- Sulfonylurea: cheap but hypo + weight gain
Clinical role
- SGLT2 → HF/CKD benefit
- Metformin remains a common inexpensive base
- Insulin if severe/catabolic hyperglycemia
- Match therapy to goals, cost + kidney function
Practical pearls
- GLP-1/GIP-GLP-1 → weight + ASCVD benefit
Self-check
- What should drive antihyperglycemic drug selection?
Comorbidities, goals, cost, and kidney function.
- Which class has major HF/CKD benefit?
SGLT2 inhibitors.
Drugs in this class (35)
All drug classes · Open the interactive console ↗
